After you receive the kit, all the components should be stored in the refrigerator (4-8°C) also up to 18 months. Long term storage, improper storage conditions and large temperature fluctuation cycles may cause precipitates in the TMB solution. These precipitates should not affect the assay noticeably. Nevertheless, if you observe such precipitates, we recommend to avoid them by allowing them to sink to the bottom.
Performance Characteristics
Average IC50 7 ng/ml
Detection Range
0-500 ng/ml Average IC50: 7 ng/ml
General Description
Semaglutide is a therapeutically effective analog of glucagon-like peptide-1 (GLP-1). GLP-1 is an incretin hormone with important effects on glycemic control and body weight regulation, particularly relevant in people with type 2 diabetes (T2D). This ELISA was developed with serum from rabbits immunized with Semaglutide coupled to a carrier protein. Immunogen: Synthetic peptide H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18diacid-γ-Glu-OEG-OEG)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH coupled to carrier protein.
Standard Curve
Citations
Publication ()
Have you cited DEIASL092 in a publication? Let us know and earn a reward for your research.
Background
Type 2 diabetes mellitus (T2DM) refers to a metabolic disease in which the body's insulin deficiency or insulin utilization is reduced, resulting in a sustained increase in blood sugar in patients. Patients are often accompanied by abnormal lipid metabolism, and most patients are accompanied by obesity. Long-term exposure of the body to high blood sugar and high fat environments can lead to lesions in blood vessels and nerves, which can harm the heart, kidneys and other organs. Metformin is one of the most commonly used drugs to treat T2DM, but long-term use of metformin alone will cause a series of complications. This shows that simply increasing the dose of hypoglycemic drugs can no longer effectively improve the therapeutic effect of T2DM patients. Therefore, in the treatment of T2DM patients, the issue of obesity also needs to be paid attention. Studies have found that glucagon-like peptide-1 receptor agonist (GLP-1RA) is an effective drug to achieve good blood sugar control in patients with type 2 diabetes (T2DM). GLP-1RA not only lowers blood sugar but also has weight loss effects.
Figure 1. Mechanism of absorption for oral semaglutide.(Source: Seidu S, et al., 2021)
Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogue. It is a long-acting dosage form developed based on the basic structure of liraglutide. It is more effective in treating type 2 diabetes. As a glucagon-like peptide 1 receptor agonist, semaglutide increases the production of insulin, a hormone that lowers blood sugar, by mimicking the effects of glucagon-like peptide-1 (GLP-1). It also appears to promote the growth of pancreatic cells, which are responsible for the production and release of insulin. Additionally, it inhibits the production of glucagon, a hormone that promotes glycogenolysis (the release of stored carbohydrates from the liver) and gluconeogenesis (the synthesis of new glucose). It reduces food intake by reducing appetite and slowing digestion in the stomach, helping to reduce body fat.
Because semaglutide not only has the function of lowering blood sugar and lipids, it also shows efficacy and effects on immune regulation, antioxidant, and promotion of growth and development. Therefore, researchers are still actively exploring its therapeutic effects on other diseases. To support these related studies, we provide a detection tool for the in vitro quantitative determination of semaglutide in serum and plasma - the semaglutide ELISA kit. It can easily and conveniently determine the concentration of semaglutide in serum and plasma samples.
Alternative Names
Ozempic Rybelsus GLP-1 receptor agonist
References
1. Seidu S, et al., Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? Prim Care Diabetes. 2021, 15(1):59-68.
Q: As Semaglutide binds strongly to albumin, is there any pre-treatment needed for quantitation determination of the Semaglutide using your kit?
A: No additional treatment is necessary.
Customer Reviews
My Review for Semaglutide ELISA Kit
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chronic weight management. This paper reviews data on the mechanism of action, weight-loss and cardiometabolic efficacy, and safety of semaglutide 2.4 mg/week for obesity. Semaglutide has demonstrated the largest weight loss of any obesity medication to date with reductions of approximately 15% of initial weight at 68 weeks, accompanied by improvements in cardiovascular risks factors and physical functioning. The approval of this medication provides patients with greater options for weight management.
Wegovy (semaglutide): a new weight loss drug for chronic weight management
Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabetes. This literature review summarizes and discusses the weight loss results from the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), PIONEER (Peptide Innovation for Early Diabetes Treatment), and STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programs. The SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide (a new GLP-1 homolog), respectively, on participants with type 2 diabetes. The STEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglutide on patients with obesity. Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss.
COA
Publication 
Figure 1. Mechanism of absorption for oral semaglutide.(Source: Seidu S, et al., 2021)
Loading ......
